TNF inhibitor
Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.
Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of active psoriatic arthritis (PsA).
It seems like every conference we are presented with data on the newest biologic for treatment of psoriatic arthritis, but the question is, do we need it?
Oral presentation (6937) discussed that issue and addressed our need for a more personalized approach to the treatment of PsA.
Md Yuzaiful Md Yusof Yuz6Yusof
4 years ago
@almirall_m I don't monitor routinely. High rate of seroconversion post-TNFi but only small cases of TNFi-induced SLE (mild mostly). To screen with ANA if develop SLE features
Md Yuzaiful Md Yusof Yuz6Yusof
4 years ago
Due to significant interest in our Tweet about #POS0204 #EULAR2021, let's vote. Would you monitor #ANA in patients receiving therapy with #TNF inhibitors?🧐@RheumNow
Eric Dein ejdein1
4 years ago
Yesterday at #EULAR2021: Spacing trial: success in taper anti-TNF for stable SpA. POS0229 C-OPTIMSE study: Certolizumab w/d for SpA remission (continue full dose vs. 1/2 dose vs. placebo). Placebo group had ⬆️ activity scores, 77% flared. Ok to taper, but won't stop Rx @Rheumnow
Dr. John Cush RheumNow
4 years ago
#EULAR2021 and EULAR IQ
Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.
https://t.co/BkHjhOUqNU https://t.co/4JS1yGiJHg
Meral K. El Ramahi, MD MeralElRamahiMD
4 years ago
2021 GRAPPA STRONG recs (cont'd):
*⃣Crohn's Dz & UC: TNFi (not ETN), IL12/23i
🚫strong rec against IL17i
2021 GRAPPA CONDITIONAL recs for:
*⃣ Uveitis: TNFi (not ETN), CyA
*⃣ Crohn's Dz & UC: IL23i, JAKi, MTX
OP0229 #EULAR2021 @RheumNow https://t.co/AWyKqSapWG
Janet Pope Janetbirdope
4 years ago
Sex differences in response to bDMARDs in RA, PsA & SpA? YES. Data from BIOREG- 477 RA, 150 PsA, 312 SpA treated with rap TNFi. Men respond better to TNFi in all groups POS0208 #EULAR2021 @RheumNow @eular_org https://t.co/7FoI3p0qwe
Poster Hall